Prestonian.....
They had all that and MORE and still could not compete. They failed to get FDA and now one of the comparators has. They have a low cash burn rate ..lol their staff cost are only $142,000. Pretty much working for nothing......that is not going to last in a real world. They say improved but I can't find anything to say what those improvements are ie have they sorted out the shelf life issues that plagued it over the China deal.
They are not better placed now than they have ever been, they have to deal with better competitors products, brunt bridges with supplies and a trashed product name and goodwill flushed down the toilet to boot.
Look I am sorry for being negative, but I am not seeing one thing that has changed other than all the above you mentioned was already in place, and my god how many CR did we have to endure and it still was not enough cash to get lift of and that is with revenue and sales coming in. Just be realistic the horse has bolted and this new board is going to have a hell of time trying to get it back in the yard. Dr Suns patents pretty much got ripped end of story.
- Forums
- ASX - By Stock
- SBN
- Ann: Initial Oraline Product Run Completed
Ann: Initial Oraline Product Run Completed , page-23
-
- There are more pages in this discussion • 32 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add SBN (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
BTH
BIGTINCAN HOLDINGS LIMITED
David Keane, Co-Founder & CEO
David Keane
Co-Founder & CEO
Previous Video
Next Video
SPONSORED BY The Market Online